Aileron Therapeutics Files 8-K: Material Definitive Agreement
Ticker: RNTX · Form: 8-K · Filed: Jul 26, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Jul 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $50,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-filing
Related Tickers: ALRN
TL;DR
Aileron Therapeutics (ALRN) signed a material definitive agreement on 7/26/24. Details to follow.
AI Summary
Aileron Therapeutics, Inc. announced on July 26, 2024, that it entered into a Material Definitive Agreement. The filing also includes other events and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Austin, Texas.
Why It Matters
This 8-K filing indicates a significant new agreement for Aileron Therapeutics, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant new risks or opportunities, requiring further analysis of the agreement's terms.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- July 26, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Austin, Texas (location) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement?
The filing states that Aileron Therapeutics, Inc. entered into a Material Definitive Agreement on July 26, 2024, but the specific details of the agreement are not provided in this summary.
When was this 8-K filing submitted?
This 8-K filing was submitted on July 26, 2024.
Where is Aileron Therapeutics, Inc. headquartered?
Aileron Therapeutics, Inc.'s principal executive offices are located at 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
What is Aileron Therapeutics, Inc.'s state of incorporation?
Aileron Therapeutics, Inc. is incorporated in Delaware.
What other items are included in this 8-K filing?
In addition to the entry into a Material Definitive Agreement, this 8-K filing also includes information on Other Events and Financial Statements and Exhibits.
Filing Stats: 1,012 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2024-07-26 16:36:00
Key Financial Figures
- $0.001 — nge On which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
- $50,000,000 — ng an aggregate offering price of up to $50,000,000 (the " Shares ") in connection with the
Filing Documents
- d868344d8k.htm (8-K) — 30KB
- d868344dex11.htm (EX-1.1) — 199KB
- d868344dex51.htm (EX-5.1) — 12KB
- g868344g0725074206089.jpg (GRAPHIC) — 2KB
- g868344g0725074928582.jpg (GRAPHIC) — 6KB
- 0001193125-24-186279.txt ( ) — 430KB
- alrn-20240726.xsd (EX-101.SCH) — 3KB
- alrn-20240726_lab.xml (EX-101.LAB) — 18KB
- alrn-20240726_pre.xml (EX-101.PRE) — 11KB
- d868344d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. d) Exhibits Exhibit No. Description 1.1 Equity Distribution Agreement, dated July 26, 2024, by and between Aileron Therapeutics, Inc. and Citizens JMP Securities, LLC. 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP. 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (contained in Exhibit 5.1 above). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aileron Therapeutics, Inc. Date: July 26, 2024 By: /s/ Brian Windsor Name: Brian Windsor, Ph.D. Title: President and Chief Executive Officer